Related Experiment Video
Updated: Oct 6, 2025
09:31
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.4K
Multivesicular Liposomes for Glucose-Responsive Insulin Delivery.
Guangqu Liu1, Suping He1, Yu Ding1
1Department of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China.
Pharmaceutics
|January 21, 2022
Summary
A novel glucose-responsive multivesicular liposome (MVL) system offers self-regulated insulin delivery for diabetes management. This intelligent system effectively controls blood glucose levels by responding to glucose fluctuations.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Endocrinology
Background:
- Diabetes management requires precise insulin delivery to maintain glycemic control.
- Current insulin delivery methods often lack responsiveness to real-time glucose fluctuations.
- Developing intelligent, self-regulated insulin delivery systems is crucial for improving patient outcomes.
Purpose of the Study:
- To develop and characterize a novel glucose-responsive multivesicular liposome (MVL) for self-regulated insulin delivery.
- To investigate the glucose-triggered insulin release mechanism of the developed MVLs.
- To evaluate the in vivo efficacy of glucose-responsive MVLs in a type 1 diabetic rat model.
Main Methods:
- Fabrication of glucose-responsive multivesicular liposomes (MVLs) using a double emulsion method.
- In vitro assessment of glucose-responsive insulin release kinetics.
- Elucidation of the glucose-responsive mechanism using Alizarin red probe and molecular docking.
- In vivo evaluation of MVLs in chemically induced type 1 diabetic rats.
Main Results:
- Glucose-responsive MVLs demonstrated effective, self-regulated insulin release in response to varying glucose concentrations in vitro.
- The glucose-responsive mechanism involves glucose oxidase catalysis, leading to MVL membrane degradation and insulin release.
- In vivo studies showed that glucose-responsive MVLs successfully regulated blood glucose levels in diabetic rats.
- The developed MVLs exhibited good biocompatibility.
Conclusions:
- Glucose-responsive MVLs represent a promising intelligent system for self-regulated insulin delivery.
- This novel approach offers a potential advancement in diabetes treatment by mimicking physiological glucose regulation.
- Further investigation into the clinical application of these biocompatible MVLs is warranted.
More Related Videos
Related Concept Videos
01:05Insulin Secretory Vesicles
5.7K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.7K
01:24Glucagon-like Receptor Agonists
461
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
461
01:27Insulin Formulations: Types and Delivery
299
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
299
01:06Oral Hypoglycemic Agents: Glinides
290
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
290
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.5K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
328
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
328